Revasc

RSS

Withdrawn

This medicine's authorisation has been withdrawn

desirudin
MedicineHumanWithdrawn

Polish is available via eTranslation, the European Commission's machine translation service.

Translate to Polish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 9 July 1997, the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Revasc, which had been approved for prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery. The marketing authorisation holder (MAH) responsible for Revasc was Canyon Pharmaceuticals Limited. 

On 18 July 2014, the European Commission issued a decision to withdraw the marketing authorisation for Revasc, following its receipt of a letter dated 19 June 2014 notifying the Commission of the MAH’s decision to voluntarily withdraw the marketing authorisation for this product for commercial reason. Revasc was not marketed in any European country. 

Pursuant to this decision, the European public assessment report for Revasc is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (190.38 KB - PDF)

Zobacz

español (ES) (40.88 KB - PDF)

Zobacz

čeština (CS) (179.38 KB - PDF)

Zobacz

dansk (DA) (40.28 KB - PDF)

Zobacz

Deutsch (DE) (41.35 KB - PDF)

Zobacz

eesti (ET) (40.16 KB - PDF)

Zobacz

ελληνικά (EL) (184.52 KB - PDF)

Zobacz

français (FR) (41.26 KB - PDF)

Zobacz

italiano (IT) (41.21 KB - PDF)

Zobacz

latviešu (LV) (181.03 KB - PDF)

Zobacz

lietuvių (LT) (176.64 KB - PDF)

Zobacz

magyar (HU) (173.94 KB - PDF)

Zobacz

Malti (MT) (184.37 KB - PDF)

Zobacz

Nederlands (NL) (40.57 KB - PDF)

Zobacz

polski (PL) (188.74 KB - PDF)

Zobacz

português (PT) (41.33 KB - PDF)

Zobacz

română (RO) (171.2 KB - PDF)

Zobacz

slovenčina (SK) (176.83 KB - PDF)

Zobacz

slovenščina (SL) (168.36 KB - PDF)

Zobacz

suomi (FI) (40.31 KB - PDF)

Zobacz

svenska (SV) (40.46 KB - PDF)

Zobacz

Product information

български (BG) (696.71 KB - PDF)

Zobacz

español (ES) (334.91 KB - PDF)

Zobacz

čeština (CS) (558.2 KB - PDF)

Zobacz

dansk (DA) (337.62 KB - PDF)

Zobacz

Deutsch (DE) (343.51 KB - PDF)

Zobacz

eesti (ET) (331.91 KB - PDF)

Zobacz

ελληνικά (EL) (754.34 KB - PDF)

Zobacz

français (FR) (324.43 KB - PDF)

Zobacz

italiano (IT) (319.92 KB - PDF)

Zobacz

latviešu (LV) (589.48 KB - PDF)

Zobacz

lietuvių (LT) (417.62 KB - PDF)

Zobacz

magyar (HU) (566.96 KB - PDF)

Zobacz

Malti (MT) (650.42 KB - PDF)

Zobacz

Nederlands (NL) (353.06 KB - PDF)

Zobacz

polski (PL) (597.35 KB - PDF)

Zobacz

português (PT) (338.51 KB - PDF)

Zobacz

română (RO) (421 KB - PDF)

Zobacz

slovenčina (SK) (578.31 KB - PDF)

Zobacz

slovenščina (SL) (534.06 KB - PDF)

Zobacz

suomi (FI) (355.44 KB - PDF)

Zobacz

svenska (SV) (339.2 KB - PDF)

Zobacz

Íslenska (IS) (361.58 KB - PDF)

Zobacz

norsk (NO) (347.23 KB - PDF)

Zobacz
Latest procedure affecting product information:IAIN/0031/G
23/01/2012
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (234.71 KB - PDF)

Zobacz

español (ES) (177.62 KB - PDF)

Zobacz

čeština (CS) (212.51 KB - PDF)

Zobacz

dansk (DA) (181.15 KB - PDF)

Zobacz

Deutsch (DE) (186.17 KB - PDF)

Zobacz

eesti (ET) (177.99 KB - PDF)

Zobacz

ελληνικά (EL) (212.16 KB - PDF)

Zobacz

français (FR) (179.52 KB - PDF)

Zobacz

italiano (IT) (176.79 KB - PDF)

Zobacz

latviešu (LV) (210.01 KB - PDF)

Zobacz

lietuvių (LT) (199.46 KB - PDF)

Zobacz

magyar (HU) (197.43 KB - PDF)

Zobacz

Malti (MT) (229.11 KB - PDF)

Zobacz

Nederlands (NL) (179.78 KB - PDF)

Zobacz

polski (PL) (210.74 KB - PDF)

Zobacz

português (PT) (179.96 KB - PDF)

Zobacz

română (RO) (220.16 KB - PDF)

Zobacz

slovenčina (SK) (208.39 KB - PDF)

Zobacz

slovenščina (SL) (183.94 KB - PDF)

Zobacz

suomi (FI) (176.24 KB - PDF)

Zobacz

svenska (SV) (181.18 KB - PDF)

Zobacz

Product details

Name of medicine
Revasc
Active substance
desirudin
International non-proprietary name (INN) or common name
desirudin
Therapeutic area (MeSH)
Venous Thrombosis
Anatomical therapeutic chemical (ATC) code
B01AE01

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery.

Authorisation details

EMA product number
EMEA/H/C/000104
Marketing authorisation holder
Canyon Pharmaceuticals Ltd.

Canyon Pharmaceuticals Limited
7th Floor
52-54 Gracechurch Street
London
EC3V 0EH
United Kingdom

Marketing authorisation issued
09/07/1997
Withdrawal of marketing authorisation
18/07/2014
Revision
12

Assessment history

This page was last updated on

Share this page